ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,096 | -99.7% | 27,326 | +158.8% | 0.11% | +86.2% |
Q3 2022 | $437,000 | -65.3% | 10,560 | -39.1% | 0.06% | -65.7% |
Q1 2022 | $1,260,000 | -28.5% | 17,345 | -17.2% | 0.17% | -23.5% |
Q4 2021 | $1,762,000 | +312.6% | 20,950 | +579.3% | 0.22% | +215.7% |
Q4 2020 | $427,000 | -1.4% | 3,084 | -69.6% | 0.07% | +40.0% |
Q4 2019 | $433,000 | +27.4% | 10,129 | +27.3% | 0.05% | +8.7% |
Q3 2019 | $340,000 | +69.2% | 7,959 | +174.4% | 0.05% | +130.0% |
Q1 2019 | $201,000 | -75.3% | 2,900 | -72.6% | 0.02% | -50.0% |
Q2 2018 | $813,000 | -9.4% | 10,582 | -39.9% | 0.04% | -14.9% |
Q1 2018 | $897,000 | -28.5% | 17,600 | +57.3% | 0.05% | -23.0% |
Q4 2015 | $1,255,000 | +30.7% | 11,188 | +12.2% | 0.06% | +29.8% |
Q3 2015 | $960,000 | +6.5% | 9,970 | +13.3% | 0.05% | +34.3% |
Q2 2015 | $901,000 | +184.2% | 8,800 | +72.5% | 0.04% | +169.2% |
Q1 2015 | $317,000 | -32.8% | 5,100 | -52.5% | 0.01% | -60.6% |
Q4 2014 | $472,000 | – | 10,748 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |